Panel Discussion: Affordability and feasibility of large scale genetic risk profiling

2019년 3월 7일

Should we do ever larger genome-wide association studies? Will large scale population sequencing studies for dementia be productive in going after rare variants? Should we be investing more effort in family-based sequencing studies? Find out what leading dementia researchers think about the trends in the field. Panelists in the session: -Dr. Jose Bras, Dementia Research Institute, University College London -Prof. Gerard D. Schellenberg, University of Pennsylvania -Dr. Cornelia van Duijn, Erasmus Medical Center Session moderated by: Dr. Kyle Vogan, Nature Genetics For other videos and dementia research-related resources, visit http://ion.illumina.com/genetics-of-dementia-resource-library-yt For Research Use Only. Not for use in diagnostic procedures. QB #6255 Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

다음을 통해 기사 공유하기: